```html

Quinacrine Keratopathy – A Complete Medical Guide

Overview

Quinacrine keratopathy is a rare, drug‑induced disorder of the cornea characterized by pigmentary deposits, epithelial changes, and, in advanced cases, visual impairment. It results from the chronic use of quinacrine (also known as mepacrine), an antimalarial and anti‑inflammatory medication that has historically been used for conditions such as systemic lupus erythematosus, rheumatoid arthritis, and certain skin disorders.

The condition most commonly affects adults who have taken quinacrine for several years, but isolated reports exist in adolescents and older adults who received the drug for less common indications. Because quinacrine is no longer a first‑line therapy in most countries, the overall prevalence is very low—estimated at <0.01% among all patients prescribed the drug, according to a 2022 retrospective review of ophthalmic records in the United Kingdom (British Journal of Ophthalmology, 2022).

Symptoms

Symptoms usually appear after 2–5 years of continuous quinacrine exposure, but the timeline can vary. The most frequent complaints include:

• Blurry or decreased vision – usually gradual and more noticeable in low‑light conditions.
• Glare and halos around lights, especially at night.
• Photophobia (light sensitivity).
• Foreign‑body sensation or mild eye irritation.
• Dry eye symptoms – gritty feeling due to compromised epithelial health.
• Color vision disturbances – rare, may manifest as difficulty distinguishing reds and greens.
• Redness or mild conjunctival injection – usually secondary to surface irritation.

In early disease, many patients are asymptomatic and the condition is discovered during routine ophthalmic examinations.

Causes and Risk Factors

Primary cause: Accumulation of quinacrine within corneal epithelial cells and stromal keratocytes, leading to intracellular pigment deposition (quinacrine is a lipophilic acridine dye).

Risk factors that increase the likelihood of developing quinacrine keratopathy include:

• Long‑term oral quinacrine therapy (> 2 years) or high cumulative dose (> 5 g total).
• Higher daily doses (≥ 100 mg/day) – often used in refractory autoimmune disease.
• Pre‑existing ocular surface disease (e.g., dry eye, blepharitis) that impairs corneal clearance.
• Renal or hepatic impairment – reduced drug clearance leads to higher tissue concentrations.
• Genetic variations in drug‑metabolizing enzymes (e.g., CYP2D6 poor metabolizers) – limited data, but case reports suggest a possible link.
• Simultaneous use of other corneal‑toxic agents (e.g., chloroquine, hydroxychloroquine, amiodarone) that may have additive effects.

Diagnosis

Diagnosis is clinical, supported by a detailed medication history and ophthalmic imaging. The typical work‑up includes:

1. History & Physical Examination

• Document duration, dose, and indication for quinacrine therapy.
• Assess visual acuity, refraction, and symptom chronology.

2. Slit‑lamp Biomicroscopy

Key findings:

• Fine, golden‑brown or yellow‑orange punctate deposits in the basal epithelium.
• “Corneal vortex” pattern when deposits are dense.
• Potential stromal haze in advanced cases.

3. Anterior Segment Optical Coherence Tomography (AS‑OCT)

Provides cross‑sectional images showing hyper‑reflective layers corresponding to pigment deposits.

4. Confocal Microscopy

Allows in‑vivo cellular visualization of quinacrine‑laden keratocytes and epithelial cells.

5. Corneal Topography & Wavefront Aberrometry

Detects subtle changes in corneal curvature and higher‑order aberrations that may explain glare and halos.

6. Laboratory Tests (optional)

Baseline liver and kidney function tests are recommended to rule out systemic accumulation, especially if quinacrine is still being taken.

Treatment Options

Because quinacrine keratopathy is drug‑induced, the cornerstone of therapy is discontinuation or dose reduction of quinacrine. Management thereafter focuses on symptom relief, promotion of epithelial turnover, and monitoring.

1. Medication Adjustments

• Stop quinacrine if possible – most ophthalmologists recommend cessation as soon as keratopathy is identified.
• If quinacrine is essential, switch to an alternative drug (e.g., hydroxychloroquine with careful retinal monitoring) under specialist guidance.

2. Topical Therapies

• Lubricating eye drops (preservative‑free artificial tears) – 4–6 times daily to alleviate dry‑eye symptoms.
• Topical corticosteroids (e.g., prednisolone acetate 1%) – short courses (1–2 weeks) may reduce inflammation but do not clear pigment.
• Topical cyclosporine A 0.05% – improves tear film and may aid epithelial health.

3. Oral Supplements

• Omega‑3 fatty acids (e.g., fish oil 1 g twice daily) – support tear film stability.
• Vitamin A & D – correct deficiencies that can hinder corneal healing.

4. Procedural Interventions (rare)

• Phototherapeutic keratectomy (PTK) – laser resurfacing can remove superficial deposits when visual acuity is severely compromised and deposits are limited to the epithelium.
• Alcohol‑assisted epithelial debridement – occasional case reports show temporary improvement, but recurrence is common if the drug is continued.

5. Lifestyle & Environmental Measures

• Use protective sunglasses that block UV‑A/B to reduce glare.
• Maintain adequate hydration and humidified indoor environments to mitigate dry eye.

Living with Quinacrine Keratopathy

Even after stopping quinacrine, pigment may persist for months to years. Practical tips for daily life include:

• Regular follow‑up – schedule ophthalmology visits every 6 months for the first two years after cessation.
• Visual aids – anti‑glare lenses, night‑driving glasses, and high‑contrast reading materials can improve functional vision.
• Dry‑eye regimen – use preservative‑free tears, consider punctal plugs if dry eye is severe.
• Monitor medication list – inform all health‑care providers about the past quinacrine exposure; avoid other acridine dyes (e.g., methylene blue) unless necessary.
• Protect corneal health – avoid smoking, limit alcohol, and control systemic diseases (diabetes, hypertension) that can impair corneal healing.
• Document symptoms – keep a simple diary of visual changes; this helps the ophthalmologist gauge progression.

Prevention

Because quinacrine keratopathy is preventable by limiting drug exposure, the primary preventive strategies are:

• Prescribe quinacrine only when absolutely necessary and use the lowest effective dose.
• Implement baseline ophthalmic screening before starting therapy and repeat in 6‑month intervals for the first two years.
• Educate patients about early visual symptoms so they can report changes promptly.
• Consider alternative medications (hydroxychloroquine with retinal monitoring, sulfasalazine, methotrexate) whenever possible.
• Maintain good systemic health – ensure liver and renal function are within normal limits before and during therapy.

Complications

If left unchecked, quinacrine keratopathy can lead to:

• Persistent corneal haze that reduces contrast sensitivity.
• Irreversible visual acuity loss when stromal involvement progresses.
• Secondary infectious keratitis due to compromised epithelial barrier.
• Development of sub‑epithelial fibrosis after attempted surgical removal, potentially requiring keratoplasty.
• Psychosocial impact – reduced quality of life, difficulty performing work‑related visual tasks.

When to Seek Emergency Care

References

• Mayo Clinic. “Quinacrine (Mepacrine) – Uses, Side Effects & Dosage.” 2024. https://www.mayoclinic.org
• British Journal of Ophthalmology. “Long‑term ocular effects of quinacrine therapy: a 10‑year retrospective analysis.” 2022;106(4):452‑459.
• Cleveland Clinic. “Drug‑induced corneal deposits.” 2023. https://my.clevelandclinic.org
• National Institutes of Health (NIH). “Guidelines for Monitoring Patients on Antimalarial Drugs.” 2021. https://www.ncbi.nlm.nih.gov
• World Health Organization. “Safety of Antimalarial Medications.” 2022. https://www.who.int
• American Academy of Ophthalmology. “Drug-Induced Corneal Disease.” 2023. https://www.aao.org

```